Cherchez une société par raison sociale, ticker ou ISIN, puis ouvrez sa fiche.
Performance
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
En 2025, l’exercice se solde par une perte de 140,1 M $US. Le flux de trésorerie libre, lui, s’établit à -109,1 M $US.
Le nombre d’actions est passé de 27,7 M à 57,9 M entre 2021 et 2025, soit 108,9 % de titres en plus : le bénéfice se partage entre davantage de parts.